Mechanisms of Antidepressant Non-Response in Late-Life Depression
Late-Life Depression
Sponsor: NIMH
Enrolling: Male and Female Patients
Study Length: 8 Weeks
Clinic Visits: 8
IRB Number: 6836
U.S. Govt. ID: NCT01931202
Contact: Kaleigh O'Boyle: 646-774-8652 / kaleigh.oboyle@nyspi.columbia.edu
Additional Study Information: In this research study, you may receive treatment for depression with an FDA approved medication called escitalopram (Lexapro) or placebo. Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain. A placebo is a sugar pill. The purpose of this study is to determine how treatment response may change depending on how studies are designed. Participants in this study will also undergo Magnetic Resonance Imaging (MRI) in order to investigate the brain responses associated with depression.
This study is closed
Do You Qualify?
Are you 60-90 years of age? Yes No
Have you been diagnosed with bipolar disorder? Yes No
Have you been diagnosed with Alzheimer's Disease, Vascular Dementia, or Parkinson's Disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Kaleigh O'Boyle
kaleigh.oboyle@nyspi.columbia.edu
646-774-8652